The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV
infection and cryptococcal meningitis and to determine the MTD of the drug. To evaluate the
pharmacokinetics, including cerebrospinal fluid (CSF) penetration, of amphotericin B when
administered with RMP-7.